2025年4月4日 周五
Home > Archive>Volume 30, Issue 2, 2022 >180-184
PDF HTML XML Export Cite reminder
Research progress on the mechanism of broad-spectrum antiplatelet effect of novel P2Y12 receptor antagonist ticagrelor
CSTR:
[cstr]
Author:
Affiliation:

Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning 116011, China)

Clc Number:

R54

  • Article
    • | |
  • Metrics
    • |
  • Reference [30]
    • |
  • Related
    • |
  • Cited by
    • | |
  • Comments
    Abstract:

    Dual antiplatelet therapy is the cornerstone of antithrombotic therapy in patients with acute coronary syndrome. Aspirin and P2Y12 receptor antagonists are commonly used antiplatelet drugs in clinic. At present, new P2Y12 receptor antagonists, especially ticagrelor monotherapy, are the subject of in-depth research in the field of antiplatelet optimization therapy. Studies have found that P2Y12 receptor antagonists can reduce thromboxane A2 receptor expression and thromboxane A2 production in platelets. Ticagrelor has broad-spectrum antiplatelet mechanism. This article summarizes the relevant research on the antiplatelet mechanism of new P2Y12 receptor antagonists, especially ticagrelor, and proposes new ideas for optimizing antiplatelet therapy.

    Reference
    [1] VALGIMIGLI M, BUENO H, BYRNE R A, et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).Eur Heart J, 8,9(3):213-260.
    [2] MEHRAN R, BABER U, SHARMA S K, et al.Ticagrelor with or without aspirin in high-risk patients after PCI.N Engl J Med, 9,1(21):2032-2042.
    [3] JENNINGS L K.Role of platelets in atherothrombosis.Am J Cardiol, 9,3(3 Suppl):4A-10A.
    [4] DEHARO P, CUISSET T.Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome.Trends Cardiovasc Med, 0,0(4):198-202.
    [5] PEREIRA N L, RIHAL C S, SO D Y F, et al.Clopidogrel pharmacogenetics.Circ Cardiovasc Interv, 9,2(4):e007811.
    [6] CHEN Y, DONG W, WAN Z, et al.Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome:a pharmacodynamic analysis.Int J Cardiol, 5,1:545-546.
    [7] MCFADYEN J D, JACKSON S P.Differentiating haemostasis from thrombosis for therapeutic benefit.Thromb Haemost, 3,0(5):859-867.
    [8] ARMSTRONG P C, LEADBEATER P D, CHAN M V, et al.In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.J Thromb Haemost, 1,9(3):552-561.
    [9] YANACHKOV I B, CHANG H, YANACHKOVA M I, et al.New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.Eur J Med Chem, 6,7:204-218.
    [10] KIRKBY N S, LEADBEATER P D, CHAN M V, et al.Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel.J Thromb Haemost, 1,9(10):2103-2105.
    [11] GRZESK G, KOZINSKI M, TANTRY U S, et al.High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells.Biomed Res Int, 3,3:928271.
    [12] ARMSTRONG P C, DHANJI A R, TUCKER A T, et al.Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy.J Thromb Haemost, 0,8(3):613-615.
    [13] BHAVARAJU K, GEORGAKIS A, JIN J, et al.Antagonism of P2Y12 reduces physiological thromboxane levels.Platelets, 0,1(8):604-609.
    [14] ROGER S, PAWLOWSKI M, HABIB A, et al.Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation.FEBS Lett, 4,6(1-3):227-235.
    [15] WU C C, HWANG T L, LIAO C H, et al.The role of PAR4 in thrombin-induced thromboxane production in human platelets.Thromb Haemost, 3,0(2):299-308.
    [16] SHANKAR H, GARCIA A, PRABHAKAR J, et al.P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.J Thromb Haemost, 6,4(3):638-647.
    [17] TRENK D, STONE G W, GAWAZ M, et al.A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents:results of the TRIGGER-PCI study.J Am Coll Cardiol, 2,9(24):2159-2164.
    [18] CHAN M V, KNOWLES R B, LUNDBERG M H, et al.P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation.Br J Clin Pharmacol, 6,1(4):621-633.
    [19] KNOWLES R B, WARNER T D.Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy.Pharmacol Ther, 9,3:83-90.
    [20] WITTFELDT A, EMANUELSSON H, BRANDRUP-WOGNSEN G, et al.Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.J Am Coll Cardiol, 3,1(7):723-727.
    [21] NYLANDER S, FEMIA E A, SCAVONE M, et al.Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism.J Thromb Haemost, 3,1(10):1867-1876.
    [22] FELIU C, PEYRET H, BRASSART-PASCO S, et al.Ticagrelor prevents endothelial cell apoptosis through the adenosine signalling pathway in the early stages of hypoxia.Biomolecules, 0,0(5):740.
    [23] KHAN J N, GREENWOOD J P, NAZIR S A, et al.Infarct size following treatment with second-versus third-generation P2Y12 antagonists in patients with multivessel coronary disease at ST-segment elevation myocardial infarction in the CvLPRIT study.J Am Heart Assoc, 6,5(6):e003403.
    [24] SABBAH M, NEPPER-CHRISTENSEN L, KBER L, et al.Infarct size following loading with ticagrelor/prasugrel versus clopidogrel in ST-segment elevation myocardial infarction.Int J Cardiol, 0,4:7-12.
    [25] BONELLO L, LAINE M, KIPSON N, et al.Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.J Am Coll Cardiol, 4,3(9):872-877.
    [26] VAN DER POL E, BOING A N, HARRISON P, et al.Classification, functions, and clinical relevance of extracellular vesicles.Pharmacol Rev, 2,4(3):676-705.
    [27] HEEMSKERK J W, MATTHEIJ N J, COSEMANS J M.Platelet-based coagulation:different populations, different functions.J Thromb Haemost, 3,1(1):2-16.
    [28] VAJEN T, MAUSE S F, KOENEN R R.Microvesicles from platelets:novel drivers of vascular inflammation.Thromb Haemost, 5,4(2):228-236.
    [29] GASECKA A, NIEUWLAND R, VAN DER POL E, et al.P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.Cardiol J, 9,6(6):782-789.
    [30] HALIM H, PINKAEW D, CHUNHACHA P, et al.Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel.PLoS One, 9,4(6):e218934.
    Related
    Cited by
Get Citation

ZHAO Kaikai, BAI Junqin, ZHANG Bo. Research progress on the mechanism of broad-spectrum antiplatelet effect of novel P2Y12 receptor antagonist ticagrelor[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2022,30(2):180-184.

Copy
Share
Article Metrics
  • Abstract:319
  • PDF: 1576
  • HTML: 0
  • Cited by: 0
History
  • Received:August 01,2020
  • Revised:October 01,2020
  • Online: January 07,2022
Article QR Code

You are the 27163 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025